Phathom Pharmaceuticals, Inc. PHAT Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$30.37M-43.6% | -$21.15M+29.4% | -$29.97M+60.5% | -$75.81M+19.6% | -$94.32M-26.7% | ||
| $110K-14.1% | $128K-17.9% | $156K-9.3% | $172K-2.8% | $177K-8.3% | ||
| $5.53M-1.4% | $5.61M-39.7% | $9.3M+12.4% | $8.27M+49.3% | $5.54M-17.2% | ||
| $844K+4.3% | $809K+4.4% | $775K+5.6% | $734K+5.5% | $696K+10.7% | ||
| $2.6M-88.4% | $22.34M+393% | $4.53M-69.6% | $14.89M+712% | -$2.43M-114% | ||
| -$665K— | —— | —— | $1.85M-85.0% | $12.33M+121% | ||
| -$3.12M-111% | $27.57M+2,375% | $1.11M-91.0% | $12.38M+278% | -$6.96M-135% | ||
| $171K-98.1% | $8.86M+737% | -$1.39M+77.7% | -$6.25M— | $0— | ||
| -$1.61M-85.5% | -$865K+28.5% | -$1.21M+8.5% | -$1.32M+27.0% | -$1.81M-102% | ||
| -$829K— | —— | —— | —— | $0— | ||
| -$15.65M-213% | -$5M+64.6% | -$14.12M+77.5% | -$62.73M+26.1% | -$84.93M-33.8% | ||
| $61K-29.9% | $87K+222% | $27K-72.2% | $97K+439% | $18K+260% | ||
| -$61K+29.9% | -$87K-222% | -$27K+72.2% | -$97K-439% | -$18K-260% | ||
| $173.25M— | $0— | $0— | $0— | $0-100% | ||
| $229.05M— | —— | —— | —— | $0— | ||
| $591K-53.3% | $1.27M+332% | $293K+266% | $80K— | $0-100% | ||
| $66.64M+68,801% | -$97K+64.2% | -$271K-439% | $80K— | $0-100% | ||
| $50.93M+1,082% | -$5.19M+64.0% | -$14.41M+77.0% | -$62.75M+26.1% | -$84.95M-127% | ||
| $4.94M-9.1% | $5.43M+0.6% | $5.4M+1.7% | $5.31M+1.6% | $5.23M+8.5% | ||
| $3.54M— | —— | —— | —— | $8.04M-30.3% | ||
| $844K+4.3% | $809K+4.4% | $775K+5.6% | $734K+5.5% | $696K+10.7% | ||
| -$157K-331% | $68K+580% | $10K— | —— | $92K-51.3% | ||
| $10K-88.9% | $90K+36.4% | $66K+154% | $26K-35.0% | $40K-2.4% | ||
| -$6.92M— | —— | -$1.39M— | —— | -$7.81M-233% | ||
| $0— | —— | —— | —— | $899K+649% | ||
| -$1.61M-85.5% | -$865K+28.5% | -$1.21M+8.5% | -$1.32M+27.0% | -$1.81M-102% | ||
| -$128K— | —— | —— | —— | $0— | ||
| $121.97M— | $0— | —— | —— | $0— | ||
| $0+100% | -$51K-221% | $42K+220% | -$35K-180% | $44K+450% | ||
| $3.5M— | $0— | $0— | $0— | $0-100% | ||
| $2.07M— | —— | $3.13M— | —— | $2.13M— | ||
| $1.54M— | —— | $1.12M— | —— | $1.85M— | ||
| -$15.71M-209% | -$5.09M+64.0% | -$14.14M+77.5% | -$62.83M+26.0% | -$84.95M-33.9% | ||
| -$15.71M-209% | -$5.09M+64.0% | -$14.14M+77.5% | -$62.83M+26.0% | -$84.95M-33.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Phathom Pharmaceuticals, Inc. generate?
- Phathom Pharmaceuticals, Inc. (PHAT) generated -$97.5M in operating cash flow over the trailing twelve months.
- What is Phathom Pharmaceuticals, Inc.'s free cash flow?
- After $272.0K of capital expenditures, Phathom Pharmaceuticals, Inc.'s free cash flow was -$97.8M over the trailing twelve months, up 65.4% year over year.
- Where does Phathom Pharmaceuticals, Inc.'s cash flow data come from?
- Every line is extracted from Phathom Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
